Insmed to Participate at February Investment Conferences

Leerink Global Healthcare Conference 2015

BRIDGEWATER, N.J.--()--Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the following investor conferences in February:

  • Canaccord Genuity’s Rare Disease Biopharma Day on February 3, 2015 in New York City; and
  • 2015 Leerink Global Healthcare Conference taking place in New York City on February 11-12, 2015. Will Lewis, President and Chief Executive Officer of Insmed, will participate in a fireside chat with Leerink Partners’ analyst, Joseph Schwartz, on February 11, 2015 at 11:30 a.m. Eastern time.

Mr. Lewis’ fireside chat at the 2015 Leerink Global Healthcare Conference will be webcast live on the internet and can be accessed by visiting the Investors section of the Company's website at www.insmed.com. A replay of the webcast will be archived on the Insmed website for 90 days following the presentation.

About Insmed

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKAYCE™, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS-1009 (treprostinil), the Company’s novel inhalation formulation of a proven prostacyclin for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. For more information, please visit http://www.insmed.com.

Forward-looking statements

This release contains forward-looking statements. Words, and variations of words, such as “intend,” “expect,” “will,” “anticipate,” “believe,” “continue,” “propose” and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of clinical trials and clinical data, the anticipated benefits of Insmed’s products, the anticipated timing of regulatory submissions, and the ability to obtain required regulatory approvals, bring products to market and successfully commercialize products constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of European, Canadian, U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting the Company’s product candidates, delays in product development or clinical trials or other studies, patent disputes and other intellectual property developments relating to the Company’s product candidates, unexpected regulatory actions, delays or requests, the failure of clinical trials or other studies or results of clinical trials or other studies that do not meet expectations, the fact that subsequent analyses of clinical trial or study data may lead to different (including less favorable) interpretations of trial or study results or may identify important implications of a trial or study that are not reflected in Company’s prior disclosures, and the fact that trial or study results or subsequent analyses may be subject to differing interpretations by regulatory agencies, the inability to successfully develop the Company’s product candidates or receive necessary regulatory approvals, the inability to make product candidates commercially successful, changes in anticipated expenses, changes in the Company’s financing requirements or ability to raise additional capital, and other risks and challenges detailed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2013 and its subsequent quarterly reports on Form 10-Q. Investors are cautioned not to place undue reliance on any forward-looking statements that speak only as of the date of this news release. The Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances or changes in its expectations.

Contacts

Investor Relations:
LHA
Anne Marie Fields, Senior Vice President
212-838-3777
afields@lhai.com
or
Bruce Voss, Managing Director
310-691-7100
bvoss@lhai.com

Contacts

Investor Relations:
LHA
Anne Marie Fields, Senior Vice President
212-838-3777
afields@lhai.com
or
Bruce Voss, Managing Director
310-691-7100
bvoss@lhai.com